In patients with a recurrence of stage III colorectal cancer, deficient MMR was associated with better survival, but this benefit was limited to patients with proximal tumors; mutations in BRAF were associated with worse survival and worse survival for BRAF or KRAS-mutant tumors was more strongly associated with distal tumors [143]. This evidence concerns the gene KRAS and colorectal cancer.